3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasm Metastasis
2
Sarcoma
1
Recurrence
1
Prostatic Hyperplasia
1
Multiple Endocrine Neoplasia Type 1
1
Liver Diseases
1
Leiomyoma
1
Hyperplasia
1
Head and Neck Neoplasms
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Interventions
Capecitabine
6
Irinotecan
5
Fluorouracil
5
Cisplatin
5
Oxaliplatin
4
Leucovorin
4
Gemcitabine
4
apatinib
3
Sorafenib
3
Bevacizumab
3
tislelizumab
2
pembrolizumab
2
Sunitinib
2
Radiotherapy
2
Paclitaxel
2
Immune Checkpoint Inhibitors
2
Cyclophosphamide
2
Cetuximab
2
Aspirin
2
Ascorbic Acid
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
sintilimab
1
regorafenib
1
pyrotinib
1
pemigatinib
1
lutetium Lu 177 dotatate
1
huachansu
1
halofantrine
1
guadecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Digestive System Neoplasms
×
Microspheres
×
Clear all
NCT02208804
2016-11-09
SIM
UMC Utrecht
Phase 2/3
Unknown
25 enrolled